Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jan;218(1):107.e1-107.e8.
doi: 10.1016/j.ajog.2017.09.020. Epub 2017 Oct 3.

Contraception after medication abortion in the United States: results from a cluster randomized trial

Affiliations
Randomized Controlled Trial

Contraception after medication abortion in the United States: results from a cluster randomized trial

Corinne H Rocca et al. Am J Obstet Gynecol. 2018 Jan.

Abstract

Background: Understanding how contraceptive choices and access differ for women having medication abortions compared to aspiration procedures can help to identify priorities for improved patient-centered postabortion contraceptive care.

Objective: The objective of this study was to investigate the differences in contraceptive counseling, method choices, and use between medication and aspiration abortion patients.

Study design: This subanalysis examines data from 643 abortion patients from 17 reproductive health centers in a cluster, randomized trial across the United States. We recruited participants aged 18-25 years who did not desire pregnancy and followed them for 1 year. We measured the effect of a full-staff contraceptive training and abortion type on contraceptive counseling, choice, and use with multivariable regression models, using generalized estimating equations for clustering. We used survival analysis with shared frailty to model actual intrauterine device and subdermal implant initiation over 1 year.

Results: Overall, 26% of participants (n = 166) had a medication abortion and 74% (n = 477) had an aspiration abortion at the enrollment visit. Women obtaining medication abortions were as likely as those having aspiration abortions to receive counseling on intrauterine devices or the implant (55%) and on a short-acting hormonal method (79%). The proportions of women choosing to use these methods (29% intrauterine device or implant, 58% short-acting hormonal) were also similar by abortion type. The proportions of women who actually used short-acting hormonal methods (71% medication vs 57% aspiration) and condoms or no method (20% vs 22%) within 3 months were not significantly different by abortion type. However, intrauterine device initiation over a year was significantly lower after the medication than the aspiration abortion (11 per 100 person-years vs 20 per 100 person-years, adjusted hazard ratio, 0.50; 95% confidence interval, 0.28-0.89). Implant initiation rates were low and similar by abortion type (5 per 100 person-years vs 4 per 100 person-years, adjusted hazard ratio, 2.41; 95% confidence interval, 0.88-6.59). In contrast to women choosing short-acting methods, relatively few of those choosing a long-acting method at enrollment, 34% of medication abortion patients and 53% of aspiration abortion patients, had one placed within 3 months. Neither differences in health insurance nor pelvic examination preferences by abortion type accounted for lower intrauterine device use among medication abortion patients.

Conclusion: Despite similar contraceptive choices, fewer patients receiving medication abortion than aspiration abortion initiated intrauterine devices over 1 year of follow-up. Interventions to help patients receiving medication abortion to successfully return for intrauterine device placement are warranted. New protocols for same-day implant placement may also help patients receiving medication abortion and desiring a long-acting method to receive one.

Trial registration: ClinicalTrials.gov NCT01360216.

Keywords: abortion; implant; intrauterine device; long-acting reversible contraception; medical abortion; medication abortion; postabortion contraception; randomized trial.

PubMed Disclaimer

Conflict of interest statement

Dr Cadwallader is a Nexplanon trainer (Merck). The other authors report no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan-Meier curve of IUD initiation among abortion patients Kaplan-Meier curve and IUD initiation among medication and aspiration abortion patients. The figure depicts the proportions of participants initiating an intrauterine device over the 1-year study, by medication vs aspiration abortion. IUD, intrauterine device.
FIGURE 2
FIGURE 2
Kaplan-Meier curve of implant initiation among abortion patients Kaplan-Meier curve of subdermal implant initiation among medication and aspiration abortion patients. This figure depicts the proportions of participants initiating an implant over the 1-year study, by medication vs aspiration abortion.

Similar articles

Cited by

References

    1. Jones RK, Jerman J. Abortion incidence and service availability in the United States, 2014. Perspect Sex Reprod Health. 2017;49:17–27. - PMC - PubMed
    1. Cameron S, Glasier A, Dewart H, Johnstone A. Women’s experiences of the final stage of early medical abortion at home: results of a pilot survey. J Fam Plan Reprod Health Care. 2010;36:213–6. - PubMed
    1. Finer LB, Wei J. Effect of mifepristone on abortion access in the United States. Obstet Gynecol. 2009;114:623–30. - PubMed
    1. Centers for Disease Control and Prevention, Department of Health and Human Services. US medical eligibility criteria for contraceptive use, 2010. MMWR Morb Mort Wkly Rep. 2010;59:2.
    1. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev. 2004:CD001777. - PubMed

Publication types

Associated data